HKSE · 1652.HK
Fusen Pharmaceutical Company Limited
HK$1.03+HK$0.03 (+3.0%)
Fusen Pharmaceutical Company Limited’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
Loading market information…
HKSE · 3737.HK · HKD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:47 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Zhongzhi Pharmaceutical Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 36.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Zhongzhi Pharmaceutical Holdings Limited’s forward annual dividend is HK$0.05 per share, paid annual. The forward yield is 8.0% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Zhongzhi Pharmaceutical Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Zhongzhi Pharmaceutical Holdings Limited, an investment holding firm based in the People's Republic of China, focuses on the entire lifecycle of pharmaceutical products, from research and development to manufacturing and distribution. Its operations are structured across three main divisions: pharmaceutical production, management of its physical retail pharmacy chain, and its online pharmacy platform. The company offers Chinese patent medicines and traditional Chinese decoction pieces, marketed under prominent brands such as Zeus, Liumian, and Caojinghua. In addition to its core pharmaceutical activities, Zhongzhi also produces and sells food products and traditional Chinese herbs, manages properties, and offers detection and testing services. By the end of 2021, the company managed a network of 398 self-owned retail pharmacies. Of these, 361 were approved for medical insurance payments and are situated in Zhongshan, Guangdong Province, operating under the Zeus brand. Established in 1993, the company's headquarters are also located in Zhongshan, PRC. Crystal Talent Investment Group Limited holds a controlling stake in Zhongzhi Pharmaceutical Holdings Limited.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:57 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$1.03+HK$0.03 (+3.0%)
Fusen Pharmaceutical Company Limited’s quoted price sits in the lower half of its reported 52-week range, 28.47% below the high.
HK$5.49-HK$0.01 (-0.09%)
Charmacy Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.81% below the high.
HK$0.50+HK$0.02 (+3.09%)
Kato (Hong Kong) Holdings Limited’s quoted price sits in the upper half of its reported 52-week range, 7.41% below the high.
HK$0.71+HK$0.03 (+3.65%)
Vincent Medical Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 34.86% below the high.
HK$0.36+HK$0.02 (+5.88%)
Wai Yuen Tong Medicine Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 26.53% below the high.
HK$0.62-HK$0.03 (-3.88%)
Yunkang Group Limited’s quoted price sits in the lower half of its reported 52-week range, 50.4% below the high.
HK$0.51-HK$0.02 (-3.81%)
Austar Lifesciences Limited’s quoted price sits in the lower half of its reported 52-week range, 60.24% below the high.
HK$0.34HK$0.00 (0.0%)
Modern Chinese Medicine Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 89.57% below the high.
